article thumbnail

Alzheimer’s therapeutics market to reach $6.8 billion by 2032

European Pharmaceutical Review

In 2015, Alzheimer’s Therapeutics International found there was an estimated 46.8 According to Alzheimer’s Therapeutics International in 2015, 58 percent of people with dementia live in developing countries, but by 2050 this will rise to 68 percent. percent, and driven largely by collaboration of existing players, reach $6.8

article thumbnail

Ex-Merck & Co scientist accused of stealing trade secrets could face jail

pharmaphorum

Quadri, formerly Merck’s head of medical and scientific affairs, immune oncology, has been charged with one count of theft of trade secrets and one count of unauthorised transmission of trade secrets, some relating to the multi-billion dollar cancer immunotherapy Keytruda (pembrolizumab).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

IO Biotech raises $155m to develop breakthrough cancer vaccine

pharmaphorum

The Series B fundraiser follows the FDA’s decision to grant Breakthrough Therapy designation last month for a combination of its lead immune-oncology therapies IO102 and IO103, with anti-PD-1 monoclonal antibodies for patients with metastatic melanoma.

article thumbnail

Cancer vaccines: providing the edge in oncology

pharmaphorum

According to a report by IQVIA last year, there were 3,500 oncology-focused therapeutic candidates in the pipeline, which represents a 75% increase on figures seen in 2015. Using a vaccine to utilise the patient’s own immune system to fight cancer is particularly attractive because of the targeted approach made possible by this technology.

Vaccines 134
article thumbnail

New cancer vaccine method boosts potency and scope

World Pharma News

Vaccines to treat cancers have been around since 2010, the first being approved for prostate cancer, and another in 2015 for melanoma. One hurdle is the difficulty in finding antigens in tumors that look foreign enough to trigger an immune response.

article thumbnail

Sandoz receives US FDA approval for biosimilar Hyrimoz® high-concentration formulation

LifeProNow

Since launching the first biosimilar in the US in 2015, Sandoz has proven biosimilars create early and expanded patient access to life-altering medicines while increasing healthcare savings and creating competition that fuels innovation and development of new and enhanced treatments in areas of unmet need.

article thumbnail

Lead Pharma signs $308m deal to develop small molecule drugs with Roche

pharmaphorum

Lead Pharma has signed a potential 260 million euro ($308 million) deal with Roche to develop small molecule drugs for immune diseases. The company has been working with Sanofi since 2015 on a small molecule targeting ROR gamma, a regulator of T-helper 17 immune cells. Roche last year signed a $792.5 The US biotech got $42.5